ANI Pharmaceuticals’ (ANIP) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of ANI Pharmaceuticals (NASDAQ:ANIP) in a report released on Monday morning,Benzinga reports. HC Wainwright currently has a $94.00 target price on the specialty pharmaceutical company’s stock.

ANIP has been the subject of a number of other reports. Raymond James upped their target price on shares of ANI Pharmaceuticals from $81.00 to $83.00 and gave the stock an “outperform” rating in a research note on Wednesday, September 18th. Piper Sandler started coverage on ANI Pharmaceuticals in a research report on Friday, October 11th. They set an “overweight” rating and a $68.00 price target for the company. StockNews.com cut shares of ANI Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Saturday, September 7th. Finally, Truist Financial boosted their price target on shares of ANI Pharmaceuticals from $60.00 to $62.00 and gave the stock a “hold” rating in a research report on Tuesday, October 22nd. Two analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $77.33.

ANI Pharmaceuticals Stock Down 1.2 %

Shares of NASDAQ ANIP opened at $61.00 on Monday. ANI Pharmaceuticals has a 52-week low of $48.20 and a 52-week high of $70.81. The stock has a market cap of $1.28 billion, a P/E ratio of -112.25 and a beta of 0.71. The company has a debt-to-equity ratio of 0.62, a quick ratio of 3.07 and a current ratio of 3.97. The firm has a 50 day moving average price of $58.61 and a 200 day moving average price of $61.47.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its earnings results on Friday, November 8th. The specialty pharmaceutical company reported $1.34 earnings per share for the quarter, topping the consensus estimate of $1.09 by $0.25. ANI Pharmaceuticals had a return on equity of 15.64% and a net margin of 5.01%. The firm had revenue of $148.30 million for the quarter, compared to analyst estimates of $144.37 million. During the same period in the previous year, the company posted $1.05 earnings per share. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. Analysts expect that ANI Pharmaceuticals will post 3.5 EPS for the current year.

Institutional Investors Weigh In On ANI Pharmaceuticals

Several hedge funds have recently bought and sold shares of the company. Texas Permanent School Fund Corp raised its stake in ANI Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 13,194 shares of the specialty pharmaceutical company’s stock valued at $912,000 after buying an additional 172 shares during the period. Louisiana State Employees Retirement System lifted its holdings in ANI Pharmaceuticals by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 7,700 shares of the specialty pharmaceutical company’s stock valued at $490,000 after purchasing an additional 200 shares during the last quarter. Arizona State Retirement System boosted its position in ANI Pharmaceuticals by 4.7% during the second quarter. Arizona State Retirement System now owns 4,702 shares of the specialty pharmaceutical company’s stock worth $299,000 after purchasing an additional 211 shares during the period. Simplicity Wealth LLC boosted its position in ANI Pharmaceuticals by 3.5% during the second quarter. Simplicity Wealth LLC now owns 6,733 shares of the specialty pharmaceutical company’s stock worth $429,000 after purchasing an additional 227 shares during the period. Finally, California State Teachers Retirement System increased its holdings in shares of ANI Pharmaceuticals by 1.5% in the first quarter. California State Teachers Retirement System now owns 16,175 shares of the specialty pharmaceutical company’s stock valued at $1,118,000 after purchasing an additional 233 shares during the last quarter. 76.05% of the stock is currently owned by institutional investors and hedge funds.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. The company manufactures oral solid dose products; semi-solids, liquids, and topicals; controlled substances; and potent products, as well as performs contract development and manufacturing of pharmaceutical products.